Artiva Biotherapeutics, Inc. Income Statement
ARTV|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Artiva Biotherapeutics, Inc. reported $0 in revenue and $84M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $33.5M |
| SG&A Expense | $20.3M | $13.9M |
| R&D Expense | $69.5M | $50.3M |
| Operating Income | -$89.8M | -$30.7M |
| Income Tax | $0 | $72.0K |
| Net Income | -$83.9M | -$28.7M |
| EPS (Basic) | -$5.81 | -$35.78 |
| EPS (Diluted) | -$5.81 | -$35.78 |
| Shares Outstanding | 11.3M | 802.7K |
| Operating Margin | - | -91.6% |
| Profit Margin | - | -85.8% |